cry cell intl - CCEL

CCEL

Close Chg Chg %
3.56 0.07 1.97%

Closed Market

3.63

+0.07 (1.97%)

Volume: 22.49K

Last Updated:

Jan 9, 2026, 3:07 PM EDT

Company Overview: cry cell intl - CCEL

CCEL Key Data

Open

$3.58

Day Range

3.39 - 3.63

52 Week Range

3.19 - 8.79

Market Cap

$28.52M

Shares Outstanding

8.06M

Public Float

3.79M

Beta

0.67

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.06

Yield

1,836.16%

Dividend

$0.15

EX-DIVIDEND DATE

May 21, 2025

SHORT INTEREST

N/A

AVERAGE VOLUME

12.91K

 

CCEL Performance

1 Week
 
3.50%
 
1 Month
 
-8.27%
 
3 Months
 
-19.78%
 
1 Year
 
-50.00%
 
5 Years
 
-54.60%
 

CCEL Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About cry cell intl - CCEL

Cryo-Cell International, Inc. is cord blood bank, which engages in providing stem cell cryopreservation services and advancing regenerative medicine. It operates through the following segments: Cellular Processing and Cryogenic Storage, and Prepacyte CB. The Cellular Processing and Cryogenic Storage segment focuses on the collection and preservation of umbilical cord blood and tissue stem cells for family use. The Prepacyte CB segment refers to the processing technology used to process umbilical cord blood stem cells. The company was founded in 1989 and is headquartered in Oldsmar, FL.

CCEL At a Glance

Cryo-Cell International, Inc.
700 Brooker Creek Boulevard
Oldsmar, Florida 34677
Phone 1-813-749-2100 Revenue 31.99M
Industry Other Transportation Net Income 402.10K
Sector Transportation 2024 Sales Growth 2.05%
Fiscal Year-end 11 / 2025 Employees 82
View SEC Filings

CCEL Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 176.939
Price to Sales Ratio 2.226
Price to Book Ratio N/A
Price to Cash Flow Ratio 11.85
Enterprise Value to EBITDA 16.756
Enterprise Value to Sales 2.521
Total Debt to Enterprise Value 0.16

CCEL Efficiency

Revenue/Employee 390,074.463
Income Per Employee 4,903.598
Receivables Turnover 4.376
Total Asset Turnover 0.508

CCEL Liquidity

Current Ratio 0.581
Quick Ratio 0.551
Cash Ratio 0.162

CCEL Profitability

Gross Margin 73.641
Operating Margin 11.852
Pretax Margin 8.767
Net Margin 1.257
Return on Assets 0.639
Return on Equity N/A
Return on Total Capital -142.538
Return on Invested Capital N/A

CCEL Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital -4,584.919
Total Debt to Total Assets 19.998
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital -3,124.846
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Cry Cell Intl - CCEL

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
28.88M 30.34M 31.34M 31.99M
Sales Growth
-7.26% +5.03% +3.32% +2.05%
Cost of Goods Sold (COGS) incl D&A
9.82M 9.91M 9.57M 8.43M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.33M 1.81M 1.71M 1.02M
Depreciation
1.24M 1.71M 1.61M 953.60K
Amortization of Intangibles
89.00K 96.00K 96.00K 68.00K
COGS Growth
+0.01% +0.89% -3.48% -11.87%
Gross Income
19.06M 20.42M 21.78M 23.55M
Gross Income Growth
-10.61% +7.16% +6.62% +8.16%
Gross Profit Margin
+65.99% +67.33% +69.48% +73.64%
2021 2022 2023 2024 5-year trend
SG&A Expense
14.68M 15.97M 18.29M 19.76M
Research & Development
49.87K 384.79K 1.17M 1.24M
Other SG&A
14.63M 15.58M 17.12M 18.52M
SGA Growth
+2.49% +8.79% +14.54% +8.08%
Other Operating Expense
- - 1.16M 3.74M
-
Unusual Expense
(769.42K) 28.11K 11.88M (871.14K)
EBIT after Unusual Expense
3.99M 4.43M (12.13M) 4.66M
Non Operating Income/Expense
100 409.02K 3.44K 6.58K
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
1.38M 1.52M 1.24M 1.86M
Interest Expense Growth
-10.69% +10.36% -18.73% +50.77%
Gross Interest Expense
1.38M 1.52M 1.24M 1.86M
Interest Capitalized
- - - -
-
Pretax Income
2.61M 3.32M (13.36M) 2.80M
Pretax Income Growth
-48.18% +27.10% -502.67% +120.98%
Pretax Margin
+9.04% +10.94% -42.64% +8.77%
Income Tax
527.71K 547.54K (3.84M) 2.40M
Income Tax - Current - Domestic
- 2.28M 2.91M 2.71M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- (1.73M) (6.75M) (308.97K)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
2.08M 2.77M (9.52M) 402.10K
Minority Interest Expense
- - - -
-
Net Income
2.08M 2.77M (9.52M) 402.10K
Net Income Growth
-42.52% +33.02% -443.57% +104.22%
Net Margin Growth
+7.21% +9.14% -30.38% +1.26%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
2.08M 2.77M (9.52M) 402.10K
Preferred Dividends
- - - -
-
Net Income Available to Common
2.08M 2.77M (9.52M) 402.10K
EPS (Basic)
0.256 0.3274 -1.1416 0.0494
EPS (Basic) Growth
-46.71% +27.89% -448.69% +104.33%
Basic Shares Outstanding
8.14M 8.47M 8.34M 8.13M
EPS (Diluted)
0.2492 0.3267 -1.1416 0.049
EPS (Diluted) Growth
-44.04% +31.10% -449.43% +104.29%
Diluted Shares Outstanding
8.36M 8.48M 8.34M 8.21M
EBITDA
4.55M 6.27M 1.46M 4.81M
EBITDA Growth
-28.48% +37.87% -76.66% +228.85%
EBITDA Margin
+15.74% +20.67% +4.67% +15.05%

Snapshot

Average Recommendation HOLD Average Target Price 8.50
Number of Ratings 1 Current Quarters Estimate -0.09
FY Report Date 02 / 2026 Current Year's Estimate -0.42
Last Quarter’s Earnings -0.09 Median PE on CY Estimate N/A
Year Ago Earnings 0.11 Next Fiscal Year Estimate N/A
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 1 1 1 N/A
Mean Estimate -0.09 -0.09 -0.42 N/A
High Estimates -0.09 -0.09 -0.42 N/A
Low Estimate -0.09 -0.09 -0.42 N/A
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 0 0 0
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Hold Hold Hold

Insider Actions for Cry Cell Intl - CCEL

Date Name Shares Transaction Value
Jul 11, 2025 Harold D. Berger Director 57,901 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $3.08 per share 178,335.08
Jul 11, 2025 Harold D. Berger Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 24, 2025 David I. Portnoy Chairman, Co-CEO; Director 50,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 24, 2025 Jill M. Taymans VP Finance, CFO 10,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 24, 2025 Mark L. Portnoy Co-CEO; Director 25,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 24, 2025 Oleg Mikulinsky Chief Information Officer 10,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Cry Cell Intl in the News